Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Comparison of Antibody Responses Following Vaccination with AstraZeneca and Sinopharm

Tue Dec 3 09:30:40 2024

(2022) Comparison of Antibody Responses Following Vaccination with AstraZeneca and Sinopharm. Iranian Journal of Immunology. pp. 321-329. ISSN 17351383 (ISSN)

Full text not available from this repository.

Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Background: Vaccines are the most effective way to prevent Coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2). Objectives: To compare the antibody response of healthy individuals vaccinated with either the AstraZeneca (ChAdOx1 nCoV-19) or the Sinopharm (BBIBP-CorV) vaccine, in those who had no prior infection with SARS-CoV-2. Methods: Thirty seven participants were included, of which 17 were administered the AstraZeneca (ChAdOx1 nCoV-19) vaccine, while 20 were given the Sinopharm (BBIBP-CorV) vaccine. SARS-CoV-2 neutralizing antibody and anti-receptor-binding domain (RBD) IgG levels were checked 4 weeks after giving the first and the second dose of either vaccine using the enzyme-linked immunosorbent assay (ELISA) technique. Results: The AstraZeneca (ChAdOx1 nCoV-19) vaccine exhibited a higher levels of anti-(RBD) IgG compared with the Sinopharm (BBIBP-CorV) in both the first (14.51 μg/ml vs. 1.160 μg/ml) and the second (46.68 μg/ml vs. 11.43 μg/ml) doses. About neutralizing Abs, the titer of the antibody was higher in the AstraZeneca (ChAdOx1 nCoV-19) recipients than in the Sinopharm (BBIBP-CorV) subjects after the first (7.77 μg/ml vs. 1.79 μg/ml, P<0.0001) and the second dose (10.36 μg/ml vs. 4.88 μg/ml, P<0.0001). Conclusions: Recipients vaccinated with two doses of the AstraZeneca (ChAdOx1 nCoV-19) had superior quantitative antibody levels than Sinopharm (BBIBP-CorV)-vaccinated subjects. These data suggest that a booster dose may be needed for the Sinopharm (BBIBP-CorV) recipients, to control the COVID-19 pandemic. © 2022, Shiraz University of Medical Sciences. All rights reserved.

Item Type: Article
Creators:
CreatorsEmail
Anvari, E.UNSPECIFIED
Talepoor, A. G.UNSPECIFIED
Vakili, M. E.UNSPECIFIED
Karami, N.UNSPECIFIED
Ataollahi, M. R.UNSPECIFIED
Najafi, G.UNSPECIFIED
Kabalitz, D.UNSPECIFIED
Ahmadi, I.UNSPECIFIED
Kalantar, K.UNSPECIFIED
Keywords: COVID-19 Neutralizing antibody Oxford-AstraZeneca Sinopharm Vaccine immunoglobulin G virus antibody virus vaccine antibody production human pandemic prevention and control vaccination Antibodies, Neutralizing Antibodies, Viral Antibody Formation ChAdOx1 nCoV-19 Humans Pandemics SARS-CoV-2 Viral Vaccines
Divisions:
Page Range: pp. 321-329
Journal or Publication Title: Iranian Journal of Immunology
Journal Index: Scopus
Volume: 19
Number: 3
Identification Number: https://doi.org/10.22034/iji.2022.94298.2300
ISSN: 17351383 (ISSN)
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/4104

Actions (login required)

View Item View Item